Nasdaq
$2.29▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.1MShares out 4.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.18Overnight26.09.18 10:354Ownership#●●●
KIORA PHARMACEUTICALS INC
Keith J. Lane, an insider at Kiora Pharmaceuticals, filed a Form 4 to report a change in his beneficial ownership of company securities. This filing provides transparency regarding insider transactions and equity holdings.…more
$2.29+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18Overnight26.09.18 10:273Ownership
KIORA PHARMACEUTICALS INC
Keith J. Lane of Kiora Pharmaceuticals has granted a limited power of attorney to company representatives to prepare and file Forms 3, 4, and 5 regarding securities transactions. This is an administrative measure to facilitate compliance with SEC reporting requirements for insiders.…more
$2.29+0.00%vs prev closeView filingShare - 9.17After-hours26.09.18 05:07SCHEDULE 13GOwnership
KIORA PHARMACEUTICALS INC
Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed a joint Schedule 13G regarding their ownership stake in Kiora Pharmaceuticals, Inc. This filing formalizes the collective holding of shares by these entities.…more
$2.29+0.00%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.19Pre-market26.08.19 20:09#●●●#●●●#●●●
Kiora Pharmaceuticals Signs Exclusive Licensing Deal with Chong Kun Dang for KIO-301…more
Kiora Pharmaceuticals has entered into an exclusive licensing agreement with Chong Kun Dang for the development and commercialization of KIO-301 in South Korea. The deal includes a $1 million upfront payment, along with potential milestone payments and royalties.…more
$2.29+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga